Supercharged NK cells, unlike primary activated NK cells, effectively target ovarian cancer cells irrespective of MHC-class I expression
The use of sNK cells in immunotherapy emerges as a potentially effective strategy to target and eliminate the majority of ovarian tumour clones, thereby providing a potential therapeutic opportunity in preventing the recurrence of the disease.
Authors
- Thomas G. Graeber (ORCID: https://orcid.org/0000-0001-8574-9181)
- Neda A. Moatamed (ORCID: https://orcid.org/0000-0002-9986-8058)
- Favour N. Esedebe (ORCID: https://orcid.org/0000-0001-6167-0647)
- Sanaz Memarzadeh
- Sara Huerta-Yepez
- Yi Jou Liao (ORCID: https://orcid.org/0000-0002-2853-5475)
- Kawaljit Kaur (ORCID: https://orcid.org/0000-0003-1936-5985)
- Ao Mei
- Tanya Singh (ORCID: https://orcid.org/0000-0003-4312-0873)
- Subramaniam Malarkannan (ORCID: https://orcid.org/0000-0002-7511-2731)
- Anahid Jewett (ORCID: https://orcid.org/0000-0002-7840-1176)
- Yash Jain (ORCID: https://orcid.org/0000-0001-5148-6811)
- Gabriella DiBernardo (ORCID: https://orcid.org/0000-0001-8022-7288)
- Po-Chun Chen (ORCID: https://orcid.org/0009-0002-7578-5482)
Institutions
- University of California, Los Angeles (US)
- Medical College of Wisconsin (US)
- Los Angeles Medical Center (US)
- Hospital Infantil de México Federico Gómez (MX)
- Versiti Blood Center of Wisconsin (US)
- Comprehensive Cardiovascular (US)
- Broad Center (US)
- VA Greater Los Angeles Healthcare System (US)
- Oklahoma State University Center for Health Sciences (US)
Publication Details
- Journal
- BMJ Oncology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/bmjonc-2024-000618
- Citations
- 9
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 7.18